<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121900</url>
  </required_header>
  <id_info>
    <org_study_id>04ACL1-010</org_study_id>
    <nct_id>NCT01121900</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)</brief_title>
  <official_title>A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered as a Single Dose) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the pharmacokinetic profiles of the test product,
      300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when
      administered as a single dose, and the reference product, 100 mg trazodone HCl
      immediate-release tablets (Apotex Corp), when administered three times daily. For this
      purpose the rate and extent of absorption of trazodone and formation of
      m-chlorophenylpiperazine (mCPP) after administration of the two formulations, were compared
      under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence Based Cmax</measure>
    <time_frame>68 hours</time_frame>
    <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC(0-tlast)</measure>
    <time_frame>68 hours</time_frame>
    <description>AUC(0-tlast) = Area under the plasma concentration curve (AUC) vs (versus) time data pairs, where tlast is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Based on AUC(0-∞)</measure>
    <time_frame>68 hours</time_frame>
    <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration vs. Time Data Pairs, for the First 24 Hours [AUC(0-24)]</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>68 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Rate Constant (λz)</measure>
    <time_frame>68 hours</time_frame>
    <description>The elimination rate constant of trazodone (Lamda z). It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour. This constant is used in half-life calculations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t½.z)</measure>
    <time_frame>68 hours</time_frame>
    <description>The elimination half-life (T½z) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trazodone HCl OAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OAD: Once A Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone HCl (Apotex Corp.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>Dosage form: Extended-release caplets containing 300 mg trazodone HCl
Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours.</description>
    <arm_group_label>Trazodone HCl OAD</arm_group_label>
    <other_name>Oleptro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone HCl</intervention_name>
    <description>Dosage form: Immediate-release tablets containing 100 mg trazodone HCl
Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period.</description>
    <arm_group_label>Trazodone HCl (Apotex Corp.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects 18 to &lt; 56 years of age.

          -  Body mass within 10% of the ideal mass in relation to height and age, according to
             Body Mass Index.

          -  Body mass not less than 53 kg.

          -  Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the laboratory reference ranges for the
             relevant laboratory tests (unless the investigator considered the deviation to be
             irrelevant for the purpose of the study).

          -  Normal 12-lead electrocardiogram (ECG) and vital signs, or abnormalities, which the
             investigator did not consider a disqualification for participation in the study.

          -  Willingness to undergo a pre- and post-study physical examination and laboratory
             investigations.

          -  Ability to comprehend and willingness to sign both statements of informed consent (for
             screening and period-related procedures).

          -  Non-smoker or past smoker who stopped the use of any form of tobacco, including snuff
             or similar products, at least 3 months before entering the study.

          -  For females, the following conditions had to be met:

               1. Had been surgically sterilized or undergone a hysterectomy, or

               2. Was of childbearing potential, and all of the following conditions were met:

                    1. Had a negative pregnancy test at screening. If this test was positive, the
                       subject was to be excluded from the study before receiving study medication.
                       In the rare circumstance that a pregnancy was discovered after the subjects
                       received the study medication, every attempt was to be made to follow such
                       subjects to term.

                    2. Had to agree to use an accepted method of contraception (i.e., spermicide
                       and barrier methods or spermicide and non-hormonal intrauterine
                       contraceptive device). The subject had to agree to continue with the same
                       method throughout the study. Hormonal contraceptives were not allowed.

               3. Females not of childbearing potential could also have been included if they had
                  no menstrual period for one year and were considered as post-menopausal.

        Exclusion Criteria:

          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional
             or intellectual problems likely to have limited the validity of consent to participate
             in the study or to have limited the ability to comply with protocol requirements.

          -  History of, or current compulsive alcohol abuse (&gt; 10 drinks weekly), or regular
             exposure to other substances of abuse.

          -  Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the
             first administration of study medication except if this would not have affected the
             outcome of the study in the opinion of the investigator. Hormonal contraceptive agents
             were not allowed.

          -  Participation in another study with an experimental drug, where the last
             administration (of previous study medication) was within 8 weeks before the first
             administration of study medication.

          -  Treatment within the previous 3 months with any drug with a well-defined potential for
             adversely affecting a major organ or system.

          -  A major illness during the 3 months before commencement of the screening period.

          -  History of hypersensitivity to the study medication or any related medication.

          -  History of bronchial asthma.

          -  History of epilepsy.

          -  History of porphyria.

          -  Relevant history or laboratory or clinical findings indicative of acute or chronic
             disease, likely to have influenced the study outcome.

          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the
             first administration of study medication.

          -  Diagnosis of hypotension made during the screening period.

          -  Diagnosis of hypertension made during the screening period or current diagnosis of
             hypertension.

          -  Resting pulse of &gt; 100 beats per minute or &lt; 40 beats per minute during the screening
             period, either supine or standing.

          -  Positive testing for HIV and/or Hepatitis B and/or Hepatitis C.

          -  Positive urine screen for drugs of abuse.

          -  Positive urine screen for tobacco use.

          -  A serum pregnancy test (beta human chorionic gonadotropin [β-HCG]) either positive or
             not performed or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17925</url>
    <description>Approved Labelling</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <results_first_submitted>June 22, 2010</results_first_submitted>
  <results_first_submitted_qc>July 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2010</results_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test (Trazodone Contramid® OAD) First</title>
          <description>Trazodone Contramid® OAD (Once-A-Day) test product (300 mg tablet once daily) dosed in first treatment phase followed by Trazodone IR (Apotex Corp.) reference product (100 mg tablet thrice daily) dosed in the second treatment phase. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in treatment period 1 and the first administration of study medication in treatment period 2.
IR = Immediate Release.</description>
        </group>
        <group group_id="P2">
          <title>Reference (Trazodone IR [Apotex Corp.]) First</title>
          <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet thrice daily) dosed in first treatment phase followed by Trazodone Contramid® OAD (Once-A-Day) test product (300 mg tablet once daily) dosed in the second treatment phase. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in treatment period 1 and the first administration of study medication in treatment period 2.
IR = Immediate Release.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive Test first and Reference first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based Cmax</title>
        <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based Cmax</title>
          <description>Cmax = Maximum plasma concentration. Measured in nanogram per milliliter (ng/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1230.7" spread="499.1"/>
                    <measurement group_id="O2" value="2947.7" spread="734.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter Cmax is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>39.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.4</ci_lower_limit>
            <ci_upper_limit>46.0</ci_upper_limit>
            <estimate_desc>Test/reference (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC(0-tlast)</title>
        <description>AUC(0-tlast) = Area under the plasma concentration curve (AUC) vs (versus) time data pairs, where tlast is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC(0-tlast)</title>
          <description>AUC(0-tlast) = Area under the plasma concentration curve (AUC) vs (versus) time data pairs, where tlast is the time of the last quantifiable concentration.
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28138.4" spread="8400.0"/>
                    <measurement group_id="O2" value="34272.4" spread="9792.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-tlast) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>80.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.2</ci_lower_limit>
            <ci_upper_limit>88.3</ci_upper_limit>
            <estimate_desc>Test/reference (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Based on AUC(0-∞)</title>
        <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Based on AUC(0-∞)</title>
          <description>AUC(0-∞) = Area under the plasma concentration curve vs time data pairs, with extrapolation to infinity (∞).
Measured in nanogram x hours per milliliter (ng*h/mL).</description>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29672.5" spread="8373.8"/>
                    <measurement group_id="O2" value="35258.5" spread="10067.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence is established when the ratio of geometric Least Squares means (LSmeans) and confidence interval calculated from the exponential of the difference between the Test and Reference product for the ln-transformed parameter AUC(0-∞) is between 80% and 125%.</non_inferiority_desc>
            <param_type>Mean ratio</param_type>
            <param_value>83.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.5</ci_lower_limit>
            <ci_upper_limit>91.1</ci_upper_limit>
            <estimate_desc>Test/reference (%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration vs. Time Data Pairs, for the First 24 Hours [AUC(0-24)]</title>
        <time_frame>24 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration vs. Time Data Pairs, for the First 24 Hours [AUC(0-24)]</title>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18331.0" spread="4966.4"/>
                    <measurement group_id="O2" value="24602.2" spread="6097.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="3.64" lower_limit="2.00" upper_limit="16.02"/>
                    <measurement group_id="O2" value="8.33" spread="1.66" lower_limit="8.33" upper_limit="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Rate Constant (λz)</title>
        <description>The elimination rate constant of trazodone (Lamda z). It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour. This constant is used in half-life calculations.</description>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Rate Constant (λz)</title>
          <description>The elimination rate constant of trazodone (Lamda z). It is the ratio of clearance to volume of distribution and is expressed in units of 1/hour. This constant is used in half-life calculations.</description>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.018"/>
                    <measurement group_id="O2" value="0.090" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t½.z)</title>
        <description>The elimination half-life (T½z) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.</description>
        <time_frame>68 hours</time_frame>
        <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Trazodone Contramid® OAD</title>
            <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
          <group group_id="O2">
            <title>Trazodone IR (Apotex Corp.)</title>
            <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t½.z)</title>
          <description>The elimination half-life (T½z) of trazodone in plasma (time it takes for the concentration of trazodone to fall to half), expressed in hours.</description>
          <population>The dataset for pharmacokinetic analysis comprised the 23 subjects who completed the study as per protocol.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="3.7"/>
                    <measurement group_id="O2" value="8.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>A total of 24 subjects were exposed to Trazodone Contramid® OAD during the study (13 during first intervention period and 11 during second intervention period).
A total of 25 subjects were exposed to Trazodone IR (Apotex Corp.) during the study (13 during first intervention period and 12 during second intervention period).</desc>
      <group_list>
        <group group_id="E1">
          <title>Trazodone Contramid® OAD</title>
          <description>Trazodone Contramid® OAD test product (300 mg tablet administered once daily) dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
        </group>
        <group group_id="E2">
          <title>Trazodone IR (Apotex Corp.)</title>
          <description>Trazodone IR (Apotex Corp.) reference product (100 mg tablet administered thrice daily)dosed in either first intervention period or second intervention period. A drug-free period of 7 to 14 calendar days separated the last administration of study medication in Phase 1 and the first administration of study medication in Phase 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication based on the results of this study is envisaged, approval from the Sponsor will be obtained and a draft manuscript will be submitted to the sponsor for scrutiny and comment. The choice of scientific journal will be mutually agreed on by the principal investigator and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

